Biogen to study higher dose of Spinraza in SMA patients
5. Spinraza | FiercePharma
Biogen bounces back with Spinraza early treatment data - PMLiVE
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
NHS labels Spinraza deal “one of the most comprehensive in the world”
Spinraza®: coverage for all SMA type 1,2,3 patients - Institut de Myologie
Biogen update on European access to Spinraza – TreatSMA
NHS to use world's most expensive drug to treat spinal muscular atrophy | NHS | The Guardian
Spinraza in the UK ‒ questions and answers – TreatSMA
U.S. FDA Approves Biogen's SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy | Biogen
Drug Puts A $750,000 'Price Tag On Life' | Kaiser Health News
Spinraza - NPS MedicineWise
These highlights do not include all the information needed to use SPINRAZA® safely and effectively. See full prescribing information for SPINRAZA. SPINRAZA (nusinersen) injection, for intrathecal useInitial U.S. Approval: 2016
Study design | SPINRAZA® (nusinersen) HCP
Hydrocephalus a side effect of Spinraza? - SMA News Today Forums
EMA opinion on broad-label approval for Spinraza – TreatSMA
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (emc)
HSE approves Spinraza after lengthy campaign by patients
What is Spinraza? Uses, Side Effects & More | TheSocialMedwork
Safety | SPINRAZA® (nusinersen) HCP
Biogen provides information on upcoming Spinraza EU label | SMA Europe